JPH08502257A - Ｐｐ１４に基づく治療 - Google Patents

Ｐｐ１４に基づく治療

Info

Publication number
JPH08502257A
JPH08502257A JP6509255A JP50925594A JPH08502257A JP H08502257 A JPH08502257 A JP H08502257A JP 6509255 A JP6509255 A JP 6509255A JP 50925594 A JP50925594 A JP 50925594A JP H08502257 A JPH08502257 A JP H08502257A
Authority
JP
Japan
Prior art keywords
polypeptide
receptor
cells
antibody
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP6509255A
Other languages
English (en)
Japanese (ja)
Inventor
タイコシンスキー，マーク・エル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JPH08502257A publication Critical patent/JPH08502257A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP6509255A 1992-09-30 1993-09-28 Ｐｐ１４に基づく治療 Pending JPH08502257A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95480292A 1992-09-30 1992-09-30
US07/954,802 1992-09-30
PCT/US1993/009216 WO1994007366A1 (fr) 1992-09-30 1993-09-28 Therapie a base de pp14

Publications (1)

Publication Number Publication Date
JPH08502257A true JPH08502257A (ja) 1996-03-12

Family

ID=25495948

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6509255A Pending JPH08502257A (ja) 1992-09-30 1993-09-28 Ｐｐ１４に基づく治療

Country Status (5)

Country Link
EP (1) EP0662782A4 (fr)
JP (1) JPH08502257A (fr)
AU (1) AU5165993A (fr)
CA (1) CA2145762A1 (fr)
WO (1) WO1994007366A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519162A (ja) * 2000-01-03 2003-06-17 ティーアール アソシエイツ，エル．エル．シー． Ｐｐ１４融合蛋白質並びに該蛋白質の製造及び使用方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111743A0 (en) * 1993-12-08 1995-01-24 Intermune Life Sciences Inc Recombinant genes expressing pp14
WO2004093907A2 (fr) * 2003-04-23 2004-11-04 Tomoaki Hoshino Agent therapeutique destine a la dermatite et/ou l'alopecie et/ou les demangeaisons, methode d'evaluation de l'agent therapeutique destine a l'alopecie et/ou les demangeaisons, et nouvel animal transgenique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5039521A (en) * 1989-01-11 1991-08-13 Hyal Pharmaceutical Corporation Immune cell proliferation inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519162A (ja) * 2000-01-03 2003-06-17 ティーアール アソシエイツ，エル．エル．シー． Ｐｐ１４融合蛋白質並びに該蛋白質の製造及び使用方法

Also Published As

Publication number Publication date
WO1994007366A1 (fr) 1994-04-14
EP0662782A1 (fr) 1995-07-19
EP0662782A4 (fr) 1995-10-25
AU5165993A (en) 1994-04-26
CA2145762A1 (fr) 1994-04-14

Similar Documents

Publication Publication Date Title
Weis et al. Structure of the human B lymphocyte receptor for C3d and the Epstein-Barr virus and relatedness to other members of the family of C3/C4 binding proteins.
US7939640B2 (en) Antibodies that bind B7L-1
JP4426724B2 (ja) Ｌｄｃａｍと称される分子
JP2008131944A (ja) 白血球免疫グロブリン様受容体（ｌｉｒ）と命名される免疫調節剤ファミリー
JP2010155846A (ja) 免疫調節のための方法および組成物
JP2001517425A (ja) Ｔ細胞共同刺激性ポリペプチド、モノクローナル抗体、ならびにその製法および使用
JP2002504818A (ja) リガンドファミリーのｎｔｎ−２メンバー
JP2930713B2 (ja) タンパク質ホルモン形成の抑制用の組成物およびその使用法
JP2718827B2 (ja) 分泌Ｍａｃ−２結合糖タンパク質
JP2000510709A (ja) 少なくとも１種のｈｌａ―ｇイソ型をその表面で発現する真核細胞、およびその使用
AU762392B2 (en) Methods and materials relating to novel CD39-like polypeptides
JPH08502257A (ja) Ｐｐ１４に基づく治療
JP2005519590A (ja) 免疫関連疾患の治療のための組成物及び方法
JP2001500013A (ja) ＨＴ▲下ｍ４▼、治療およびアッセイ方法、アゴニストおよびアンタゴニスト
JPWO2003031620A1 (ja) 新規クラスｉｉサイトカイン受容体
WO2001096564A2 (fr) Isoforme d'hla-g (hla-g7) et ses applications
US6447771B1 (en) Methods and materials relating to novel CD39-like polypeptides
JPH02481A (ja) 可溶性ｔ４の精製方法
US5837495A (en) DNA encoding interleukin-1 antagonist
US6670135B1 (en) Semaphorin polypeptides
JP2004208583A (ja) 新規免疫抑制性受容体
JP3621883B2 (ja) ウイルスがコードするセマフォリンタンパク質受容体ｄｎａおよびポリペプチド
JP2001523102A (ja) アポトーシス細胞死経路の細胞内変調因子
Naz applications in infertility and immunocontraception
Naz 3. Cloning and Sequencing of Sperm Antigens Involved in Oocyte Interaction: Clinical applications in infertility and